Sells crop protection chemicals — herbicides, insecticides and fungicides — to Indian farmers through branded products including Sumimax, Excalia Max and Lentigo, while exporting to more than 50 countries. In FY26, total revenue was ₹3,238.315 crore with PAT of ₹542.975 crore and an EBITDA margin of 20.7%. Per the disclosed segment split (year to March 2022), agro chemicals contributed 92.7% of segment revenue at ₹2,840.525 crore and "Others" 7.3% at ₹224.074 crore; FY26 investor reporting notes that domestic business grew 4% while exports declined 1%, with Africa up 26-30% YoY and herbicides up 19% for the year. Operations sit on 5 manufacturing plants and 7 offices in India, with a workforce supporting domestic field activity and export markets. Materials — raw and packaging inputs — are the dominant cost at 51% of revenue, followed by employee cost at 8.5% and other operating expenses at 12.9%. Growth capex underway includes a ₹500–600 crore Dahej greenfield over five years, ₹8–10 crore for Excalia Max manufacturing at Tarapur by March 2027, and a doubling of Bhavnagar capacity by end-CY2026. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Agro Chemicals (93%), Others (7%). Cyclical, monsoon-driven Indian agrochemical business with growing export footprint
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 3,065 | 3,511 | 2,844 | 3,149 | 3,238 |
| EBITDA (ex other income) | 600 | 667 | 475 | 632 | 655 |
| margin % | 19.6 | 19.0 | 16.7 | 20.1 | 20.2 |
| Owners' profit | 424 | 502 | 370 | 505 | 543 |
| EPS, as reported (₹) | 8.49 | 10.06 | 7.40 | 10.13 | 10.88 |
| ROE % · ROCE % | 22.0 · 29.3 | 21.1 · 27.1 | 15.1 · 20.2 | 17.4 · 22.9 | 16.0 · 21.0 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Cash from operations | 222 | 389 | 760 | 453 | 446 |
| Capex | (114) | (120) | (66) | (29) | (44) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 988 | 642 | 679 | 1,057 | 930 | 568 | 684 | 1,063 |
| Profit before tax | 260 | 117 | 133 | 241 | 238 | 102 | 148 | 288 |
| Net profit | 193 | 87 | 100 | 178 | 178 | 76 | 111 | 215 |
| EPS (₹) | 3.85 | 1.74 | 2.00 | 3.57 | 3.56 | 1.52 | 2.23 | 4.30 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| UPL LIMITED | 48,414 | 23.7 | 1.17 | 6.5 | 5.4 | 5.5 | 6.0 | 16.3 |
| PI INDUSTRIES LTD | 34,337 | 29.4 | 3.06 | 16.2 | 11.8 | 14.5 | 8.0 | 25.3 |
| SUMITOMO CHEM INDIA LTD ◆ | 23,762 | 41.0 | 7.00 | 29.6 | 16.0 | 20.8 | 4.1 | 28.9 |
| BAYER CROPSCIENCE LTD | 17,895 | 26.0 | 6.03 | — | 23.2 | 27.3 | — | 22.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 25 Aug 2026 · Sumitomo Chemical India to meet analysts on Sept 3 via Elara Capital | board shareholder meetings | low | — | — |
| 10 Aug 2026 · Sumitomo Chemical India to meet investors and analysts on 19 August 2026 | board shareholder meetings | low | — | — |
| 28 Jul 2026 · AGM results: Dividend of Rs 1.30 declared, all 10 resolutions passed | compliance | minimal | — | — |
| 27 Jul 2026 · Q1FY27 results: Revenue Rs 1,063 Cr, PAT up 20% YoY at Rs 215 Cr | investor communications | medium | — | — |
| 27 Jul 2026 · 26th AGM held: dividend declared, MD transition from 1 Sept 2026 | board shareholder meetings | low | — | — |
| 27 Jul 2026 · Q1 FY27 results: PAT up 20 percent YoY aided by insurance claim | results | high | — | — |
| 27 Jul 2026 · Non-Executive Director Ninad Gupte resigns from Sumitomo Chemical India board | management changes | medium | — | — |
| 27 Jul 2026 · Q1 FY27 Results: PAT up 20% YoY to Rs 216.5 cr, margin expands | results | high | — | — |
| 14 Jul 2026 · Sumitomo Chemical India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | compliance | minimal | — | — |
| 9 Jul 2026 · Board Meeting on July 27, 2026 to consider Q1 FY27 results | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| SHARDA CROPCHEM LTD. | 6,910 | 11.0 | 2.20 | 5.7 | 21.7 | 25.2 | 17.1 | 20.5 |
| DHANUKA AGRITECH LTD | 4,359 | 14.9 | 3.11 | 9.7 | 21.2 | 27.0 | 12.7 | 27.4 |
| RALLIS INDIA LTD | 3,833 | 23.9 | 2.26 | 12.9 | 9.7 | 12.5 | — | 0.9 |
| NACL INDUSTRIES LIMITED | 3,709 | 310.4 | 5.43 | 45.4 | 0.7 | 1.4 | 5.9 | 11.3 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 41.0 | 20.1 | 22 of 27 | 19% |
| P/B | 7.0 | 2.4 | 27 of 28 | 4% |
| ROCE | 20.8 | 12.5 | 5 of 29 | 86% |
| ROE | 16.0 | 9.2 | 5 of 28 | 85% |
| Debt / Equity | 0.0 | 0.3 | 3 of 29 | 93% |
| EBITDA margin | 28.9 | 14.8 | 1 of 28 | 100% |
| Revenue growth | 0.6 | (0.8) | 14 of 28 | 52% |
| Profit growth | 20.4 | 18.1 | 13 of 28 | 56% |
| Market cap | 23762 | 1540 | 3 of 29 | 93% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
